Abeona Therapeutics Inc. announced on July 29, 2025, a strategic HUB partnership with AscellaHealth to support the pre- and post-launch commercialization of ZEVASKYN™ (prademagene zamikeracel). AscellaHealth, a global partner in specialty pharmaceuticals, designed and executed patient-centric, end-to-end solutions to address the unique clinical, operational, and reimbursement needs of this novel autologous cell-based gene therapy. This collaboration is crucial for ensuring patient access to ZEVASKYN.
The partnership led to the creation and launch of Abeona Assist™, a highly customized patient support program. This program aims to provide a seamless experience for patients, caregivers, and healthcare providers by helping them navigate insurance benefits, financial assistance options, and logistical support. William White, Vice President of Market Access at Abeona Therapeutics, highlighted AscellaHealth's expertise in building tailored infrastructure for this complex therapeutic journey.
This integrated patient services and HUB model is instrumental in achieving optimal results for the launch of ZEVASKYN, an FDA-approved cell-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB). The partnership underscores Abeona's commitment to patient access and is expected to enhance compliance, retention, and satisfaction rates, directly supporting the commercial success of ZEVASKYN.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.